Management of hypertension in renal disease

Citation
C. Marcantoni et al., Management of hypertension in renal disease, MIN ELECT M, 25(1-2), 1999, pp. 80-83
Citations number
14
Categorie Soggetti
Endocrinology, Nutrition & Metabolism
Journal title
MINERAL AND ELECTROLYTE METABOLISM
ISSN journal
03780392 → ACNP
Volume
25
Issue
1-2
Year of publication
1999
Pages
80 - 83
Database
ISI
SICI code
0378-0392(199901/04)25:1-2<80:MOHIRD>2.0.ZU;2-B
Abstract
The treatment of systemic hypertension in chronic renal disease is now most ly based on the administration of drugs which are able to reduce proteinuri a and to slow down the progressive functional deterioration. Angiotensin-co nverting-enzyme inhibitors (ACEI), which lower both proteinuria and blood p ressure, have emerged as drugs of choice in proteinuric patients with eithe r normal renal function or mild to moderate chronic renal failure. In non p roteinuric nephropathies no controlled studies exist demonstrating the supe riority of ACEI over other drugs. In these conditions calcium antagonists m ight also be used. The approach to patients with hypertension and renal dis ease should always take into consideration the quality of the results that are to be achieved. If the aim is to control blood pressure and to protect other organs at risk, then a variety of drugs can be used. if the aim is to reduce proteinuria and slow down progression, then ACEI, possibly associat ed with calcium antagonists, are the drugs of choice.